Merck & Co., Inc. (MRK)
Merck tops earnings estimates on strong demand for Keytruda even as HPV vaccine sales fall
CNBC's Becky Quick reports on the company's quarterly earnings results.
Merck's Q3 earnings beat estimates, but company lowers guidance
Merck's stock swung between gains and losses in premarket action.
Merck third quarter better than expected, but Gardasil sales sag in China again
Merck & Co posted higher-than-expected third-quarter earnings on Thursday on strong sales of its blockbuster cancer treatment Keytruda, but the U.S. drugmaker also flagged a second straight quarter of weak demand for its Gardasil vaccine in China.
Merck tops earnings estimates on strong demand for Keytruda, new drugs even as HPV vaccine sales fall
Merck reported third-quarter revenue and adjusted earnings that topped expectations. The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health business.
Merck's Earnings Need to Reassure Investors That All Is Well
The drug company had a disastrous second quarter. It doesn't want a repeat performance.
Exploring Analyst Estimates for Merck (MRK) Q3 Earnings, Beyond Revenue and EPS
Get a deeper insight into the potential performance of Merck (MRK) for the quarter ended September 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Merck Q3 Earnings Review: Solid Financials May Be Undermined By New Keytruda Threat
Merck & Co., Inc.'s Q3 earnings report is anticipated on 31st October — next Thursday. Despite strong Q2 performance, Merck's stock fell due to a guidance downgrade related to issues with key drugs Gardasil and Winrevair. Merck's diversified pipeline includes promising oncology candidates and a new pneumococcal vaccine, but lacks a ready-made Keytruda replacement.
Merck to Report Q3 Earnings: To Buy or Not to Buy MRK Stock?
Investor focus is likely to be on the sales of Merck's blockbuster oncology medicine, Keytruda, when the company reports third-quarter earnings.
Analysts Estimate Merck (MRK) to Report a Decline in Earnings: What to Look Out for
Merck (MRK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Merck & Co., Inc. (MRK) is Attracting Investor Attention: Here is What You Should Know
Merck (MRK) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
This Biotech Stock Could Rocket 800%, Analyst Says
EF Hutton analyst Jason Kolbert initiated coverage of shares of cancer-immunotherapy biotech ImmunityBio with a Buy rating and a $30 price target on Wednesday.
